Pharma Group, KPMG, and Oxford University Clinical Research Unit launched the “Roadmap to the Future of Clinical Trials in Vietnam” on May 20, outlining strategies to position Vietnam among ASEAN’s top three clinical trial hubs by 2030. The report highlights Vietnam’s strengths, including a large, diverse population and expanded healthcare coverage, while identifying challenges such as lengthy approval processes, limited certified research sites, talent shortages, and weak incentives. It recommends policy reforms to streamline approvals and boost investment, alongside infrastructure upgrades, workforce development, and stronger public-private partnerships. A key proposal is establishing a national Centre of Excellence to accelerate trial approvals and foster collaboration. KPMG projects that with these reforms, Vietnam could conduct 86 trials by 2029, generating $749.5 million in market value and thousands of jobs. Experts emphasize that focused regulatory improvements and infrastructure investments will help Vietnam become a leading regional hub, advancing healthcare innovation and offering early access to cutting-edge treatments. (ICE HO CHI MINH CITY)

Fonte notizia: Vietnam Investment Review